Eli Lilly and Company (NYSE:LLY) Shares Down 2.1% – Should You Sell?

Eli Lilly and Company (NYSE:LLY) shares were down 2.1% during trading on Friday . The company traded as low as $877.11 and last traded at $878.1020. Approximately 2,726,538 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 3,172,125 shares. The stock had previously closed at $897.00.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Long‑term AD data: EBGLYSS (lebrikizumab‑lbkz) showed durable skin clearance and itch relief for up to four years in the ADlong Phase 3b open‑label extension — supports recurring, once‑monthly maintenance use and strengthens non‑GLP‑1 growth prospects; data to be presented at the AAD meeting. Lilly PR Newswire: EBGLYSS 4‑year data
• Positive Sentiment: Analyst upgrades: Erste Group has nudged up FY2026/27 EPS forecasts for LLY, signaling improved sell‑side expectations for earnings power. MarketBeat: LLY analyst notes
• Positive Sentiment: Brokerage sentiment remains constructive — coverage shows an average rating of “Moderate Buy,” which provides support for demand into any weakness. American Banking News: Moderate Buy rating
• Neutral Sentiment: Fund commentary: Janus Henderson’s “Forty Fund” update highlights broader market stability and earnings momentum — context that can help LLY sentiment but is not LLY‑specific. InsiderMonkey: Janus Henderson Forty Fund
• Neutral Sentiment: Industry positioning: Research reports flag Lilly as a major player in expanding oncology and mAb markets — positive long‑term but incremental near‑term impact. Yahoo Finance: Anti‑Cancer MAbS Market Report
• Neutral Sentiment: Trending coverage: Zacks and other outlets note LLY is a trending ticker — increases visibility/flow but can amplify short‑term volatility. Zacks: Why LLY is trending
• Negative Sentiment: Obesity‑market competitive pressure: Coverage comparing Lilly vs. Novo Nordisk emphasizes Novo’s current lead in obesity drugs, keeping investor focus on market share risks for Lilly’s GLP‑1 portfolio. Fool: Lilly vs Novo Nordisk
• Negative Sentiment: Peer progress in obesity: Viking Therapeutics finishing enrollment in a late‑stage obesity trial highlights rising competition and keeps near‑term market share uncertainty elevated. Yahoo Finance: VKTX enrollment
• Negative Sentiment: Acquisition/rumor noise: Speculation about Lilly‑linked deals (e.g., MDGL buyout chatter) can create headline‑driven swings and distract from fundamentals. MSN: MDGL buyout speculation

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on LLY. Wolfe Research boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. BMO Capital Markets reissued an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Daiwa Securities Group upped their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Finally, National Bank Financial set a $1,286.00 price objective on shares of Eli Lilly and Company in a report on Monday, December 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,221.44.

Eli Lilly and Company Stock Down 2.1%

The firm has a market capitalization of $829.65 billion, a price-to-earnings ratio of 38.26, a P/E/G ratio of 1.06 and a beta of 0.40. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The stock has a fifty day moving average of $1,010.46 and a two-hundred day moving average of $960.96.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same period in the previous year, the business earned $5.32 EPS. The business’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Institutional Trading of Eli Lilly and Company

Several institutional investors have recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. bought a new position in Eli Lilly and Company during the fourth quarter worth $25,000. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at $25,000. Basso Capital Management L.P. bought a new stake in Eli Lilly and Company during the fourth quarter valued at $30,000. Miller Global Investments LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $33,000. Finally, E Fund Management Hong Kong Co. Ltd. grew its position in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.